| Literature DB >> 36016175 |
Adam Webb1, Mayuri Gogoi2, Sarah Weidman1, Katherine Woolf3, Maria Zavala4, Shamez N Ladhani4, Manish Pareek2,5, Lieve Gies6, Christopher D Bayliss1.
Abstract
University students are a critical group for vaccination programmes against COVID-19, meningococcal disease (MenACWY) and measles, mumps and rubella (MMR). We aimed to evaluate risk factors for vaccine hesitancy and views about on-campus vaccine delivery among university students. Data were obtained through a cross-sectional anonymous online questionnaire study of undergraduate students in June 2021 and analysed by univariate and multivariate tests to detect associations. Complete data were obtained from 827 participants (7.6% response-rate). Self-reporting of COVID-19 vaccine status indicated uptake by two-thirds (64%; 527/827), willing for 23% (194/827), refusal by 5% (40/827) and uncertain results for 8% (66/827). Hesitancy for COVID-19 vaccines was 5% (40/761). COVID-19 vaccine hesitancy was associated with Black ethnicity (aOR, 7.01, 95% CI, 1.8-27.3) and concerns about vaccine side-effects (aOR, 1.72; 95% CI, 1.23-2.39). Uncertainty about vaccine status was frequently observed for MMR (11%) and MenACWY (26%) vaccines. Campus-associated COVID-19 vaccine campaigns were favoured by UK-based students (definitely, 45%; somewhat, 16%) and UK-based international students (definitely, 62%; somewhat, 12%). Limitations of this study were use of use of a cross-sectional approach, self-selection of the response cohort, slight biases in the demographics and a strict definition of vaccine hesitancy. Vaccine hesitancy and uncertainty about vaccine status are concerns for effective vaccine programmes. Extending capabilities of digital platforms for accessing vaccine information and sector-wide implementation of on-campus vaccine delivery are strategies for improving vaccine uptake among students. Future studies of vaccine hesitancy among students should aim to extend our observations to student populations in a wider range of university settings and with broader definitions of vaccine hesitancy.Entities:
Keywords: COVD-19; MMR; meningitis; university students; vaccine hesitancy; vaccine uptake
Year: 2022 PMID: 36016175 PMCID: PMC9415485 DOI: 10.3390/vaccines10081287
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Demographic characteristics of study participants and results of an unweighted univariate analysis of vaccine hesitancy.
| Characteristic | All Respondents | Hesitancy Group | |||
|---|---|---|---|---|---|
| Willing | Hesitant | q-Value 3 | |||
| Ethnic group |
|
| |||
| White | 479 (58%) | 428 (59%) | 16 (40%) | ||
| Asian | 203 (25%) | 180 (25%) | 6 (15%) | ||
| Black | 69 (8.3%) | 48 (6.7%) | 12 (30%) | ||
| Prefer not to say | 11 (1.3%) | 7 (1.0%) | 3 (7.5%) | ||
| Other | 65 (7.9%) | 58 (8.0%) | 3 (7.5%) | ||
| Gender | 0.4 | 0.4 | |||
| Female | 548 (66%) | 477 (66%) | 25 (62%) | ||
| Male | 255 (31%) | 222 (31%) | 14 (35%) | ||
| Other | 18 (2.2%) | 17 (2.4%) | 0 (0%) | ||
| Course studied |
| 0.060 | |||
| Humanities, Law and Social Science | 349 (42%) | 288 (40%) | 23 (57%) | ||
| Natural and Life Sciences | 302 (37%) | 261 (36%) | 14 (35%) | ||
| Medicine and allied | 176 (21%) | 172 (24%) | 3 (7.5%) | ||
| Home/international student | 0.13 | 0.2 | |||
| UK student | 734 (90%) | 643 (90%) | 31 (84%) | ||
| UK-based international student | 48 (5.9%) | 41 (5.7%) | 5 (14%) | ||
| Non-UK international student | 38 (4.6%) | 34 (4.7%) | 1 (2.7%) | ||
| Non-term residence | 0.10 | 0.14 | |||
| Local | 160 (21%) | 135 (20%) | 10 (30%) | ||
| National | 534 (68%) | 473 (69%) | 17 (52%) | ||
| International | 86 (11%) | 75 (11%) | 6 (18%) | ||
| Age group |
| 0.060 | |||
| 22+ | 297 (36%) | 266 (37%) | 8 (20%) | ||
| <= 21 | 529 (64%) | 454 (63%) | 32 (80%) | ||
| Experience of harassment | 0.8 | 0.8 | |||
| No | 752 (92%) | 659 (93%) | 35 (92%) | ||
| Yes | 62 (7.6%) | 53 (7.4%) | 3 (7.9%) | ||
| COVID-19-related death in known contact | 0.5 | 0.5 | |||
| No | 475 (58%) | 418 (58%) | 21 (52%) | ||
| Yes | 346 (42%) | 299 (42%) | 19 (48%) | ||
| Concern of vaccine side-effects (Oxford/AstraZeneca) |
|
| |||
| 1 (Strongly disagree) | 171 (21%) | 154 (22%) | 4 (10%) | ||
| 2 | 153 (19%) | 141 (20%) | 1 (2.6%) | ||
| 3 | 99 (12%) | 91 (13%) | 2 (5.1%) | ||
| 4 | 105 (13%) | 88 (13%) | 8 (21%) | ||
| 5 | 104 (13%) | 92 (13%) | 3 (7.7%) | ||
| 6 | 75 (9.4%) | 65 (9.3%) | 4 (10%) | ||
| 7 (Strongly agree) | 94 (12%) | 67 (9.6%) | 17 (44%) | ||
| Concern over hospitalisation |
| 0.068 | |||
| 0 | 392 (48%) | 337 (47%) | 25 (66%) | ||
| 1 | 339 (41%) | 305 (42%) | 8 (21%) | ||
| 2 | 60 (7.3%) | 50 (6.9%) | 3 (7.9%) | ||
| 3 | 33 (4.0%) | 28 (3.9%) | 2 (5.3%) | ||
| Concern over spreading COVID-19 to others |
|
| |||
| 0 | 82 (10.0%) | 63 (8.8%) | 11 (29%) | ||
| 1 | 226 (28%) | 203 (28%) | 10 (26%) | ||
| 2 | 297 (36%) | 264 (37%) | 12 (32%) | ||
| 3 | 216 (26%) | 189 (26%) | 5 (13%) | ||
| VAX score |
|
| |||
| 0.61 (0.50, 0.71) | 0.61 (0.50, 0.71) | 0.39 (0.25, 0.53) | |||
| Unknown 4 | 29 | 19 | 6 | ||
| Year of study | 0.050 | 0.081 | |||
| Foundation | 16 (1.9%) | 15 (2.1%) | 1 (2.5%) | ||
| 1 | 269 (33%) | 228 (32%) | 18 (45%) | ||
| 2 | 217 (26%) | 188 (26%) | 11 (28%) | ||
| 3 | 234 (28%) | 201 (28%) | 10 (25%) | ||
| 4 | 91 (11%) | 89 (12%) | 0 (0%) | ||
| Term-time residence |
|
| |||
| Home | 171 (21%) | 134 (19%) | 14 (35%) | ||
| Halls | 152 (18%) | 137 (19%) | 8 (20%) | ||
| Private | 333 (40%) | 301 (42%) | 10 (25%) | ||
| Prefer not to answer | 6 (0.7%) | 2 (0.3%) | 4 (10%) | ||
| Other | 165 (20%) | 147 (20%) | 4 (10%) | ||
| Self-determination score | 79 (71, 88) | 80 (72, 88) | 76 (68, 84) | 0.3 | 0.4 |
| Unknown 4 | 86 | 71 | 5 | ||
1 0, vaccine-willing; 1, vaccine-hesitant; N, number of participants (%); median (IQR); 2 Fisher’s exact test; Pearson’s chi-squared test; Wilcoxon rank sum test; 3 false discovery rate correction for multiple testing; 4 unknown, number participants with incomplete answers (continuous variables). Numbers for some (categorical) characteristics do not add up to the total survey population (n = 827) due to missing values. Significant p-values (<0.05) are highlighted in bold.
Multivariate analysis of vaccine hesitancy.
| Hesitancy (Unweighted) | Hesitancy (Weighted) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | N | OR 1 | 95% CI 1 | q-Value 2 | N | OR 1 | 95% CI 1 | q-Value 2 | ||
| Gender | ||||||||||
| Female | 419 | — | — | 299 | — | — | ||||
| Male | 193 | 0.84 | 0.22, 2.89 | 0.8 | >0.9 | 147 | 0.63 | 0.21, 1.85 | 0.4 | 0.6 |
| Unknown | 5 | 0.00 | >0.9 | >0.9 | ||||||
| Ethnic group | ||||||||||
| White | 377 | — | — | 271 | — | — | ||||
| Asian | 145 | 0.23 | 0.04, 1.03 | 0.072 | 0.2 | 97 | 0.24 | 0.04, 1.52 | 0.13 | 0.2 |
| Black | 43 | 6.17 | 1.48, 26.7 |
| 0.082 | 33 | 7.01 | 1.81, 27.3 |
|
|
| Other | 52 | 1.40 | 0.17, 8.22 | 0.7 | >0.9 | 39 | 1.37 | 0.12, 15.4 | 0.8 | >0.9 |
| Age group | ||||||||||
| 22+ | 230 | — | — | 169 | — | — | ||||
| <= 21 | 387 | 2.92 | 0.78, 12.6 | 0.13 | 0.3 | 276 | 3.25 | 0.73, 14.4 | 0.12 | 0.2 |
| Course studied 3 | ||||||||||
| H, Law, Soc | 240 | — | — | 175 | — | — | ||||
| Nat/Life Sci | 229 | 1.04 | 0.31, 3.44 | >0.9 | >0.9 | 158 | 0.93 | 0.32, 2.70 | 0.9 | >0.9 |
| Med/Allied | 148 | 0.16 | 0.02, 0.91 | 0.061 | 0.2 | 110 | 0.10 | 0.02, 0.50 |
|
|
| Non-term residence | ||||||||||
| Local | 120 | — | — | 92 | — | — | ||||
| National | 429 | 0.61 | 0.13, 2.79 | 0.5 | 0.8 | 305 | 0.71 | 0.20, 2.46 | 0.6 | 0.7 |
| International | 68 | 1.19 | 0.19, 7.23 | 0.8 | >0.9 | 49 | 1.76 | 0.44, 7.15 | 0.4 | 0.6 |
| Experience of harassment | ||||||||||
| No | 570 | — | — | 413 | — | — | ||||
| Yes | 47 | 2.42 | 0.34, 13.1 | 0.3 | 0.5 | 31 | 3.61 | 0.51, 25.8 | 0.2 | 0.3 |
| COVID-19-related death in known contact | ||||||||||
| No | 351 | — | — | 267 | — | — | ||||
| Yes | 266 | 5.05 | 1.65, 17.8 |
| 0.068 | 197 | 7.49 | 2.06, 27.2 |
|
|
| Concern of vaccine side-effects (Oxford/AstraZeneca) | ||||||||||
| 593 | 1.71 | 1.29, 2.37 |
|
| 610 | 1.72 | 1.23, 2.39 |
|
| |
| Concern over hospitalisation | ||||||||||
| 593 | 0.56 | 0.22, 1.25 | 0.2 | 0.3 | 610 | 0.68 | 0.24, 1.89 | 0.5 | 0.6 | |
| Concern over spreading COVID-19 to others | ||||||||||
| 593 | 0.52 | 0.27, 0.96 |
| 0.14 | 610 | 0.45 | 0.25, 0.81 |
|
| |
| Year of study | ||||||||||
| 593 | 0.81 | 0.39, 1.59 | 0.6 | 0.8 | 610 | 0.94 | 0.49, 1.81 | 0.9 | >0.9 | |
| Term-time residence | ||||||||||
| Home | 124 | — | — | 93 | — | — | ||||
| Halls | 119 | 0.23 | 0.04, 1.24 | 0.093 | 0.2 | 96 | 0.20 | 0.04, 1.03 | 0.054 | 0.13 |
| Private | 257 | 0.17 | 0.03, 0.83 |
| 0.14 | 186 | 0.13 | 0.04, 0.38 |
|
|
| Other | 117 | 0.09 | 0.00, 0.62 |
| 0.14 | 78 | 0.07 | 0.01, 0.67 |
| 0.057 |
| Self-determination score | ||||||||||
| 593 | 1.01 | 0.96, 1.06 | 0.7 | 0.9 | 610 | 1.00 | 0.96, 1.04 | >0.9 | >0.9 | |
1 OR = odds ratio, CI = confidence interval; 2 false discovery rate correction for multiple testing. 3 Abbreviations: H, humanities; Soc, social sciences; Nat/Life Sci, natural and life sciences; Med/Allied, medicine and allied courses. Significant p-values (<0.05) are highlighted in bold.
Figure 1VAX scores for a range of ethnic groups and study residences. The VAX score was determined for each student from responses to four statements about vaccines (statements 17.1, 17.2, 17.3 and 17.5 in Question 17; see Table S1 and Figure S2). VAX scores range from 0 to 1 representing high to low vaccine hesitancy. The VAX scores were determined for all individuals in four broad ethnic groups (a) or places of residence during the university term (b). Graphs show violin plots with the median scores indicated by a red circle. Box, IQR; line, IQR + 1.5 times IQR; line within box, median. p-values were derived using pairwise Dunn tests with FDR correction.
Comparative knowledge and attitudes to on campus delivery of COVID-19, MMR and MenACWY vaccines.
| Question | Vaccine Types | Possible Answers | UK Students | UK-Based International Students | Non-UK International Student | |
|---|---|---|---|---|---|---|
| Qu. 13. Have you received the following vaccines either as a child or adult | 13.1.a. MMR (measles, mumps and rubella) | Yes | 659 (90%) | 28 (58%) | 23 (61%) | <0.001 |
| Don’t Know | 58 (7.9%) | 19 (40%) | 12 (32%) | |||
| No | 17 (2.3%) | 1 (2.1%) | 3 (7.9%) | |||
| 13.2.a. MenACWY (meningitis) | Yes | 538 (73%) | 17 (35%) | 18 (47%) | <0.001 | |
| Don’t Know | 170 (23%) | 25 (52%) | 17 (45%) | |||
| No | 26 (3.5%) | 6 (12%) | 3 (7.9%) | |||
| Qu. 14. Are you aware that all of these vaccines are free in the UK for students? | 14.1.a. MMR/MenACWY | Yes | 623 (85%) | 23 (48%) | 15 (39%) | <0.001 |
| No | 111 (15%) | 25 (52%) | 23 (61%) | |||
| 14.2.b. COVID-19 | Yes | 693 (94%) | 43 (90%) | 23 (61%) | <0.001 | |
| No | 41 (5.6%) | 5 (10%) | 15 (39%) | |||
| Qu. 15. If vaccines were offered on campus, would this affect your decision to be vaccinated? | 15.1.a. MenACWY/MMR | Definitely increase | 313 (43%) | 25 (52%) | 10 (26%) | n/a |
| Somewhat increase | 103 (14%) | 8 (17%) | 9 (24%) | |||
| Neither | 290 (40%) | 13 (27%) | 18 (47%) | |||
| Somewhat decrease | 2 (0.3%) | 0 (0%) | 0 (0%) | |||
| Definitely decrease | 2 (0.3%) | 0 (0%) | 1 (2.6%) | |||
| Don’t know | 24 (3.3%) | 2 (4.2%) | 0 (0%) | |||
| 15.2.a. COVID-19 | Definitely increase | 331 (45%) | 30 (62%) | 11 (29%) | n/a | |
| Somewhat increase | 116 (16%) | 6 (12%) | 9 (24%) | |||
| Neither | 264 (36%) | 10 (21%) | 17 (45%) | |||
| Somewhat decrease | 3 (0.4%) | 2 (4.2%) | 0 (0%) | |||
| Definitely decrease | 2 (0.3%) | 0 (0%) | 1 (2.6%) | |||
| Don’t know | 18 (2.5%) | 0 (0%) | 0 (0%) |